Arecor Limited, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, is pleased to announce the appointment of Susan Lowther as Chief Financial Officer. Susan was appointed to the board with effect from 4th March 2019.
Susan has significant experience working with fast-growing life science companies and of the public markets. She was previously Chief Financial Officer and an executive director of AIM listed, IXICO plc (AIM: IXI), a neuroimaging and digital biomarker analytics clinical research firm and of French Euronext and AIM listed, Novacyt SA (EURONEXT: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics.
Her private company experience includes Chief Financial Officer of BioWisdom Limited until its acquisition by Instem plc and RiboTargets Limited until its acquisition by Vernalis plc. Susan has also held senior finance roles in other life science companies including Lonza Biologics, Celltech Group and Monsanto.
Commenting on the appointment, Dr Sarah Howell, Chief Executive Officer of Arecor, said: “I am delighted that Susan is joining the Arecor team. She brings a depth of financial and business expertise that will help us to deliver our ambitious growth plans and stated goal of building a global specialty pharmaceutical business. Following the completion of our successful capital raise last year, we are well positioned to leverage our proprietary formulation technology platform in the development of our clinical products and to expand further our technology partnerships within the pharmaceutical and biotech arenas”.
Dr Andy Richards, Chairman, also commented: “It is great news for Arecor that Susan has chosen to join the team and the board. Her experience at board level with transactions and of the public markets will provide Arecor with highly valuable expertise and resource as the Company looks to fulfil it’s exciting corporate opportunities.”
Susan Lowther added: “This is an exciting time to join Arecor and become part of an innovative and ambitious team. I look forward to working with Sarah to build the business and grow shareholder value”.
For more information, please contact:
Notes to Editors
About Arecor (www.arecor.com)
Arecor Limited is a leader in developing superior biopharmaceuticals through the application of an innovative formulation technology platform. Arecor is leveraging this platform to develop a portfolio of proprietary products that will enable improved treatments for diabetes via the innovative reformulation of approved proteins and peptides. Arecor's product portfolio also includes:
- Novel insulin formulations to deliver ultra-rapid acting insulin analogs and;
- Ultra-concentrated rapid acting insulin to enable the miniaturisation of devices,
- Stable aqueous glucagon for emergency and artificial pancreas use, and
- A series of undisclosed pre-clinical programmes.
In addition, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.